---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-002697"
form_type: "8-K"
ticker: "BTAI"
cik: "0001720893"
company_name: "BioXcel Therapeutics, Inc."
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:54:13.394458+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# BioXcel names Mark Pavao Interim CCO; plans sNDA for IGALMI at-home use

## Summary
- Mark Pavao appointed Interim Chief Commercial Officer to support potential IGALMI at-home launch.
- Company plans to submit supplemental NDA this month for FDA approval of IGALMI for at-home use.
- IGALMI targets acute agitation in bipolar disorders or schizophrenia; at-home expansion is key strategic move.

## SEC filing metadata
- accession: 0001104659-26-002697
- form_type: 8-K
- ticker: BTAI
- cik: 0001720893
- company_name: BioXcel Therapeutics, Inc.
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1720893/000110465926002697/0001104659-26-002697-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1720893/000110465926002697/tm262900d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-002697
- JSON: https://secwatch.observer/filing/0001104659-26-002697.json
- Plain text: https://secwatch.observer/filing/0001104659-26-002697.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.